Innovative Medicine
-
-
OLYSIO™ (simeprevir) Receives FDA Approval for Combination Treatment of Chronic Hepatitis C
OLYSIO™is the first once-daily protease inhibitor approved for the treatment of chronic hepatitis C in a combination antiviral regimen for adults with compensated liver disease -
Janssen Oncology Data to be Presented at 2013 American Society of Hematology (ASH) Annual Meeting
Findings Highlight Company’s Growing Hematologic Area of Focus, Including Ibrutinib, Siltuximab and Daratumumab -
IMBRUVICA™ (ibrutinib) Capsules Now Approved in the U.S. for Mantle Cell Lymphoma Patients Who Have Received at Least One Prior Therapy
Single-agent oral therapy is one of the first medications to be approved via the U.S. Food and Drug Administration’s Breakthrough Therapy Designation Pathway -
-
-
New Marketing Authorisation Application Submitted to EMA for Ibrutinib for the Treatment of Two Forms of Blood Cancer
The submission is for chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) and mantle cell lymphoma (MCL), two difficult-to-treat diseases -
New Two-Year Results Show SIMPONI® ARIA™ (GOLIMUMAB) For Infusion Inhibited Radiographic Progression In Patients With Active Rheumatoid Arthritis
Nearly 70 Percent of Patients Receiving SIMPONI ARIA at Two Years Demonstrated ACR 20 Response -
New STELARA® Data Show Inhibition Of Joint Destruction In Patients With Active Psoriatic Arthritis
Integrated Analysis of Two Pivotal Phase 3 Studies Showed STELARA Inhibited the Progression of Structural Damage at Week 24, and Demonstrated Continued Inhibition through Two Years